Atlas FDA

LimFlow System

FDA premarket approval P220025/S001 · decided 2023-10-12

Approval details

PMA number
P220025
Supplement
S001
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
LimFlow System
Generic name
Stent graft, infrapopliteal, venous arterialization
Applicant
LimFlow, Inc.
Date received
2023-09-15
Decision date
2023-10-12
Days to decision
27 days
Decision code
APPR
Product code
QWN
Advisory committee
Cardiovascular
Expedited review
No
Location
San Jose, CA
Statement
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P220025.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
LimFlow Vector (K260188)LimFlow, Inc.2026-03-18
LimFlow ARC (K251376)LimFlow, Inc.2025-05-31
LimFlow V-Ceiver (K242776)LimFlow, Inc.2025-02-14
LimFlow Vector (K221902)LimFlow, Inc.2022-12-21
LimFlow ARC (K221541)LimFlow, Inc.2022-08-31
LimFlow V-Ceiver (K222083)LimFlow, Inc.2022-08-09